BACKGROUND: This study reports an open trial of family-based cognitive-behavioral therapy (CBT) in children and adolescents with obsessive-compulsive disorder (OCD) exhibiting an onset pattern consistent with pediatric acute-onset neuropsychiatric syndrome (PANS). METHODS: Eleven primarily Caucasian youth with PANS-related OCD (range=4-14 years; 6 boys) who were incomplete responders to antibiotic treatment, received family-based CBT delivered either face-to-face or via web camera. RESULTS: All participants completing treatment (8 of 8) were considered improved at posttreatment, and average obsessive-compulsive symptom severity was reduced by 49%. Significant reductions in obsessive-compulsive symptom severity and in clinician- and parent-rated OCD-related impairment were noted. Reductions in parent- and child-rated anxiety, child-rated OCD-related impairment, and comorbid neuropsychiatric symptoms were not statistically significant. CONCLUSIONS: Gains were maintained at follow-up, with 100% (6 of 6) of those assessed remaining improved. Implications for treatment and further research are discussed.
BACKGROUND: This study reports an open trial of family-based cognitive-behavioral therapy (CBT) in children and adolescents with obsessive-compulsive disorder (OCD) exhibiting an onset pattern consistent with pediatric acute-onset neuropsychiatric syndrome (PANS). METHODS: Eleven primarily Caucasian youth with PANS-related OCD (range=4-14 years; 6 boys) who were incomplete responders to antibiotic treatment, received family-based CBT delivered either face-to-face or via web camera. RESULTS: All participants completing treatment (8 of 8) were considered improved at posttreatment, and average obsessive-compulsive symptom severity was reduced by 49%. Significant reductions in obsessive-compulsive symptom severity and in clinician- and parent-rated OCD-related impairment were noted. Reductions in parent- and child-rated anxiety, child-rated OCD-related impairment, and comorbid neuropsychiatric symptoms were not statistically significant. CONCLUSIONS: Gains were maintained at follow-up, with 100% (6 of 6) of those assessed remaining improved. Implications for treatment and further research are discussed.
Authors: Eric A Storch; Alyson C Gerdes; Jennifer W Adkins; Gary R Geffken; Jodi Star; Tanya Murphy Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-05 Impact factor: 8.829
Authors: B Birmaher; S Khetarpal; D Brent; M Cully; L Balach; J Kaufman; S M Neer Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-04 Impact factor: 8.829
Authors: Eric A Storch; Tanya K Murphy; Gary R Geffken; Giselle Mann; Jennifer Adkins; Lisa J Merlo; Danny Duke; Melissa Munson; Zoe Swaine; Wayne K Goodman Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-10 Impact factor: 8.829
Authors: S J Perlmutter; S F Leitman; M A Garvey; S Hamburger; E Feldman; H L Leonard; S E Swedo Journal: Lancet Date: 1999-10-02 Impact factor: 79.321
Authors: Adam B Lewin; John Piacentini; Alessandro S De Nadai; Anna M Jones; Tara S Peris; Gary R Geffken; Daniel A Geller; Joshua M Nadeau; Tanya K Murphy; Eric A Storch Journal: Psychol Assess Date: 2013-12-09
Authors: Eric A Storch; Tanya K Murphy; Gary R Geffken; Ohel Soto; Muhammad Sajid; Pam Allen; Jonathan W Roberti; Erin M Killiany; Wayne K Goodman Journal: Psychiatry Res Date: 2004-11-30 Impact factor: 3.222
Authors: W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney Journal: Arch Gen Psychiatry Date: 1989-11
Authors: Colin Wilbur; Ari Bitnun; Sefi Kronenberg; Ronald M Laxer; Deborah M Levy; William J Logan; Michelle Shouldice; E Ann Yeh Journal: Paediatr Child Health Date: 2018-12-09 Impact factor: 2.253
Authors: Jaime S Rosa; Joseph D Hernandez; Janell A Sherr; Bridget M Smith; Kayla D Brown; Bahare Farhadian; Talia Mahony; Sean A McGhee; David B Lewis; Margo Thienemann; Jennifer D Frankovich Journal: Pediatr Allergy Immunol Pulmonol Date: 2018-09-17 Impact factor: 1.349